Migraine hopefuls from Lilly, Allergan and Biohaven don't beat older drugs: ICER

7th November 2019 Uncategorised 0

Forthcoming migraine meds from Eli Lilly, Allergan and Biohaven took some hits in ICER’s new data review. While they’re clearly better than placebo, the new drugs don’t beat existing triptan treatments, ICER figures, except in patients who haven’t seen relief from those drugs or can’t take them at all.

More: Migraine hopefuls from Lilly, Allergan and Biohaven don't beat older drugs: ICER
Source: fierce